Table 1.
Clinicopathologic Characteristics of Primary Cutaneous Melanomas and Metastatic Melanomas, Respectively
| Variable | Category | Value |
|---|---|---|
| Primary cutaneous melanomas (n = 26) | ||
| Age, years | Range | 36–81 |
| Median | 58.0 | |
| Mean (SD) | 59.4 (11.9) | |
| Sex, n (%) | Female | 7 (26.9) |
| Male | 19 (73.1) | |
| Histologic subtype, n (%) | SSM | 12 (46.2) |
| LMM | 3 (11.5) | |
| ALM | 3 (11.5) | |
| NM | 8 (30.8) | |
| Ulceration, n (%) | Absent | 4 (16.0) |
| Present | 21 (84.0) | |
| Breslow's thickness, mm | Range | 2–16 |
| Median | 3.9 | |
| Mean (SD) | 4.6 (3.1) | |
| Mitotic index, mm2 | Range | 1–20 |
| Median | 5.0 | |
| Mean (SD) | 6.4 (5.5) | |
| T stage, n (%) | II | 5 (19.2) |
| III | 16 (61.5) | |
| IV | 5 (19.2) | |
| Site, n (%) | Head and neck | 6 (23.1) |
| Upper limbs | 6 (23.1) | |
| Lower limbs | 6 (23.1) | |
| Trunk | 8 (30.7) | |
| Follow-up time, months | Range | 4.0–188.5 |
| Median | 24.6 | |
| Mean (SD) | 41.3 (43.9) | |
| Follow-up status, n (%) | Survivor (NSR) | 9 (34.6) |
| Survivor with melanoma | 4 (15.4) | |
| Nonsurvivor (melanoma) | 6 (23.1) | |
| Nonsurvivor (other causes) | 5 (19.2) | |
| Lost to follow-up | 2 (7.7) | |
| Relapse, n (%) | No | 15 (57.7) |
| Yes | 11 (42.3) | |
| Time to relapse, months | Range | 0.33–92.5 |
| Median | 22.7 | |
| Mean (SD) | 27.4 (29.0) | |
| Metastatic melanomas (n = 27) | ||
| Age, years | Range | 30–88 |
| Median | 64.0 | |
| Mean (SD) | 63.2 (17.1) | |
| Sex, n (%) | Female | 16 (59.3) |
| Male | 11 (40.7) | |
| Metastases site, n (%) | Lymph node | 14 (51.9) |
| S.c. | 8 (29.6) | |
| Brain | 1 (3.7) | |
| Bone | 1 (3.7) | |
| Other visceral | 3 (11.1) | |
| Follow-up time, months | Range | 0.033–109.2 |
| Median | 13.1 | |
| Mean (SD) | 24.4 (26.2) | |
| Follow-up status, n (%) | Survivor | 11 (40.7) |
| Nonsurvivor | 13 (48.2) | |
| Lost to follow-up | 3 (11.1) |
ALM, acral lentiginous melanoma; LMM, lentigo malign melanoma; NM, nodular melanoma; NSR, no sign of recurrence; SSM, superficial spread melanoma.